Elenco degli articoli con argomento «psoriasi»

Dermatologia

11 set 2018

Topical Janus kinase inhibitors: A review of applications in dermatology navigation-next-alternate

J Am Acad Dermatol. 2018 Sep;79(3):535-544.

04 set 2018

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis navigation-next-alternate

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

04 set 2018

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis navigation-next-alternate

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis FoundationA Systematic Review

25 lug 2018

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation navigation-next-alternate

Expert Opin Biol Ther. 2018 Jul;18(7):727-735. doi: 10.1080/14712598.2018.1481503. Epub 2018 Jun 6.

29 mag 2018

Switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group navigation-next-alternate

Switching is a "hot" topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient's dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biologic agent to another

15 mag 2018

Buoni risultati per secukinumab contro la psoriasi del cuoio capelluto navigation-next-alternate

L'inibitore dell'interleuchina-17A (IL-17A) secukinumab migliora in maniera significativa la clearance cutanea nei pazienti affetti da psoriasi del cuoio capelluto

07 mag 2018

Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta-analysis of Psonet studies from Israel, Italy, Spain, UK navigation-next-alternate

Objectives: to assess a dose-response relationship between cumulative length of exposure to biologic therapy and risk of cancer.

29 apr 2018

Corriere.it, la nuova campagna "Chiedi al dermatologo" navigation-next-alternate

La nuova campagna "Chiedi al tuo dermatologo" sul Corriere.it

10 apr 2018

Serum levels of tumor necrosis factor-alpha in patients with psoriasis before, during and after narrow-band UVB phototherapy navigation-next-alternate

We investigate serum levels of tumor necrosis factor-? (TNF-?) in psoriatic patients before and after NB-UVB phototherapy

06 apr 2018

Childhood trauma and resilience in psoriatic patients: A preliminary report navigation-next-alternate

The aim of the study was to investigate childhood trauma and resilience in a psoriatic sample compared with healthy controls. Correlations between childhood trauma, resilience, quality of life, clinical data and psoriatic features were also evaluated

02 apr 2018

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the BADBIR navigation-next-alternate

Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the BADBIR

20 gen 2018

Association of Psoriasis With Comorbidity Development in Children With Psoriasis navigation-next-alternate

Objective: determine the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease, and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity

18 dic 2017

Bambini con psoriasi: farmaci efficaci e con una tossicità accettabile navigation-next-alternate

Quando la malattia è in forma moderata o grave serve una terapia con medicinali. Un'indagine internazionale fa il punto sugli effetti collaterali nei pazienti più piccoli

11 dic 2017

Psoriasi, più rischi per chi ha gran parte della pelle coperta da chiazze navigation-next-alternate

Uno studio Usa sostiene che quanto maggiore è la superficie cutanea interessata, tanto più alto è il pericolo di morire a causa della malattia o di altre patologie collegate

11 dic 2017

Psoriasi a placche, un nuovo farmaco funziona nei malati più gravi navigation-next-alternate

Compare di solito tra i 20 e i 30 anni ed è la forma più comune di questa malattia. Due studi hanno dimostrato l’efficacia di un medicinale biologico, che ha «pulito» la pelle

30 nov 2017

Psoriasis Severity Linked to Increased Risk of Type 2 Diabetes navigation-next-alternate

People with psoriasis have a higher risk of developing type 2 diabetes than those without psoriasis, and the risk increases dramatically based on the severity of the disease, according to a study published in the Journal of the American Academy of Dermatology

30 nov 2017

No Increase in Thromboembolic Events With Tofacitinib Treatment for Multiple Conditions navigation-next-alternate

Investigators have found no evidence of an increased risk of venous thromboembolic events (VTE) in patients treated with tofacitinib for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ulcerative colitis (UC)

13 nov 2017

Microbiota e psoriasi: che relazione c'è? navigation-next-alternate

Nelle malattie infiammatorie della cute come la psoriasi o la dermatite atopica il microbiota subisce delle variazioni significative soprattutto nel senso della perdita della normale diversità con lo sviluppo di una preponderanza di alcune specie sulle altre

13 nov 2017

Secukinumab Reduces Anxiety, Depression in Patients With Psoriatic Arthritis navigation-next-alternate

The higher anxiety and depression burden typically seen in patients with psoriatic arthritis and psoriasis is improved with secukinumab treatment

08 nov 2017

I farmaci biologici sono efficaci contro la psoriasi anche per anni navigation-next-alternate

Un'indagine svedese ha seguito i pazienti per anni, analizzando l'efficacia dei medicinali e la qualità di vita delle persone. Le conclusioni: Funzionano e sono ben tollerati